ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 55 filers reported holding ARBUTUS BIOPHARMA CORP in Q4 2016. The put-call ratio across all filers is 9.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $13,000 | – | 3,886 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,705,128 | $10,300,000 | 4.44% |
| RTW INVESTMENTS, LP | 5,666,754 | $15,754,000 | 0.59% |
| COWEN AND COMPANY, LLC | 926,200 | $2,575,000 | 0.22% |
| Hudson Bay Capital Management LP | 850,000 | $2,363,000 | 0.05% |
| LADENBURG THALMANN FINANCIAL SERVICES INC. | 1,774,915 | $4,934,000 | 0.03% |
| Point72 Asset Management, L.P. | 1,897,284 | $5,274,000 | 0.03% |
| 683 Capital Management, LLC | 77,368 | $215,000 | 0.02% |
| Secure Asset Management, LLC | 10,000 | $28,000 | 0.02% |
| Qube Research & Technologies Ltd | 166,138 | $462,000 | 0.01% |
| Verition Fund Management LLC | 174,455 | $485,000 | 0.01% |